Genomic BCR‐ABL1 breakpoints in pediatric chronic myeloid leukemia
M Krumbholz, M Karl, JT Tauer… - Genes …, 2012 - Wiley Online Library
Chronic myeloid leukemia (CML) is a rare disease in children and adolescents and various
aspects—from molecular genesis to therapy regimen—have been taken over from studies …
aspects—from molecular genesis to therapy regimen—have been taken over from studies …
[HTML][HTML] Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
NCP Cross, A Hochhaus, MC Müller - Annals of hematology, 2015 - Springer
Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic
indicator for patients with chronic myeloid leukemia, but historically, there has been …
indicator for patients with chronic myeloid leukemia, but historically, there has been …
[HTML][HTML] Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic …
Recent studies indicate that 40% of chronic myeloid leukemia patients who achieve
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain …
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain …
Leukemia stem cells
U Testa - Annals of hematology, 2011 - Springer
Leukemia-initiating cells (LICs) or leukemia stem cells (LSCs) are defined by their ability to
form tumors after xenotransplantation in immunodeficient mice and appear to be rare in most …
form tumors after xenotransplantation in immunodeficient mice and appear to be rare in most …
[HTML][HTML] IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients
K Zhao, LL Yin, DM Zhao, B Pan, W Chen… - … journal of clinical and …, 2014 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a clonal disease from hematopoietic stem cells.
Surviving leukemia stem cells (LSCs) and progenitor cells are a potential source for CML …
Surviving leukemia stem cells (LSCs) and progenitor cells are a potential source for CML …
Current developments in molecular monitoring in chronic myeloid leukemia
JE Marum, S Branford - Therapeutic advances in …, 2016 - journals.sagepub.com
Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors
CV Ichim - Stem Cells Translational Medicine, 2014 - academic.oup.com
Tyrosine kinase inhibitors such as imatinib mesylate have changed the clinical course of
chronic myeloid leukemia; however, the observation that these inhibitors do not target the …
chronic myeloid leukemia; however, the observation that these inhibitors do not target the …
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
JV Melo, DM Ross - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …